Gossamer Bio (GOSS) Change in Receivables (2024 - 2026)
Gossamer Bio (GOSS) posted quarterly Change in Receivables of -$3.0 million for Q1 2026, down 338.96% year-over-year from $1.2 million in Q1 2025, and down 199.7% quarter-over-quarter from $3.0 million in Q4 2025.
Gossamer Bio (GOSS) Change in Receivables (2024 - 2026) Analysis & Trends
Gossamer Bio's Change in Receivables history runs 3 years deep, the most recent figure standing at -$3.0 million for Q1 2026.
- In Q1 2026, Change in Receivables fell 338.96% year-over-year to -$3.0 million; the TTM figure through Mar 2026 stood at $2.7 million (down 59.46% YoY), while the FY2025 annual figure was $6.9 million, up 29.06% from the prior year.
- Change in Receivables for Q1 2026 stood at -$3.0 million, down from $3.0 million in the prior quarter.
- The five-year high for Change in Receivables was $3.6 million in Q2 2024, with the low at -$3.0 million in Q1 2026.
- The 3-year median for Change in Receivables is $1.5 million (2025), against an average of $1.2 million.
- The sharpest annual moves came in 2025 and 2026: Change in Receivables jumped 338.72% in 2025, then tumbled 338.96% in 2026.
- Gossamer Bio's Change in Receivables stood at -$1.2 million in 2024, then surged by 338.72% to $3.0 million in 2025, then slumped by 199.7% to -$3.0 million in 2026.
- Business Quant data shows GOSS's Change in Receivables at -$3.0 million in Q1 2026, $3.0 million in Q4 2025, and $1.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Gossamer Bio | 49.15 Mn | -7.87 Mn | - | -3.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.15 Mn |
| Jun 30, 2026 | -3.15 Mn |
| Mar 31, 2026 | -2.98 Mn |
| Mar 31, 2026 | -2.98 Mn |
| Dec 31, 2025 | 2.98 Mn |
| Dec 31, 2025 | 2.98 Mn |
| Sep 30, 2025 | 1.66 Mn |
| Sep 30, 2025 | 1.66 Mn |
| Jun 30, 2025 | 996,000.00 |
| Jun 30, 2025 | 996,000.00 |
| Mar 31, 2025 | 1.25 Mn |
| Mar 31, 2025 | 1.25 Mn |
| Dec 31, 2024 | -1.25 Mn |
| Dec 31, 2024 | -1.25 Mn |
| Sep 30, 2024 | 2.96 Mn |
| Sep 30, 2024 | 2.96 Mn |
| Jun 30, 2024 | 3.63 Mn |
| Jun 30, 2024 | 3.63 Mn |